Research Progress on the Inflammatory Effects of Long Non-coding RNA in Traumatic Brain Injury
- PMID: 35359568
- PMCID: PMC8961287
- DOI: 10.3389/fnmol.2022.835012
Research Progress on the Inflammatory Effects of Long Non-coding RNA in Traumatic Brain Injury
Abstract
Globally, traumatic brain injury (TBI) is an acute clinical event and an important cause of death and long-term disability. However, the underlying mechanism of the pathophysiological has not been fully elucidated and the lack of effective treatment a huge burden to individuals, families, and society. Several studies have shown that long non-coding RNAs (lncRNAs) might play a crucial role in TBI; they are abundant in the central nervous system (CNS) and participate in a variety of pathophysiological processes, including oxidative stress, inflammation, apoptosis, blood-brain barrier protection, angiogenesis, and neurogenesis. Some lncRNAs modulate multiple therapeutic targets after TBI, including inflammation, thus, these lncRNAs have tremendous therapeutic potential for TBI, as they are promising biomarkers for TBI diagnosis, treatment, and prognosis prediction. This review discusses the differential expression of different lncRNAs in brain tissue during TBI, which is likely related to the physiological and pathological processes involved in TBI. These findings may provide new targets for further scientific research on the molecular mechanisms of TBI and potential therapeutic interventions.
Keywords: immune response; inflammatory pathways; long non-coding RNA; therapy; traumatic brain injury.
Copyright © 2022 Wang, Li, Ding, Peng, Xiao, Chen and Cheng.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
References
-
- Albert V., Arulselvi S., Agrawal D., Pati H. P., Pandey R. M. (2019). Early posttraumatic changes in coagulation and fibrinolysis systems in isolated severe traumatic brain injury patients and its influence on immediate outcome. Hematol. Oncol. Stem Cell Therapy 12 32–43. 10.1016/j.hemonc.2018.09.005 - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources
